Pebrilzo Becomes Second FDA-Approved Perjeta Biosimilar for HER2-Positive Breast Cancer but Cannot Launch Before Third ...
The Food and Drug Administration has approved Pebrilzo, a biosimilar to the breast cancer drug Perjeta, for adults with HER2-positive breast cancer, Biocon Biologics announced Nov. 16. The drug, known generically as pertuzumab-qcay, is approved for the …